The Current Product Pipeline Is Comprised of HER3- and C-Met-Targeted Eosomes for Solid Tumors
click image to enlarge

All products are available for co-development or licensing.
Eos-001
- HER3-targeted Eosomes with doxorubicin payload in preclinical development
- Applications: Triple-negative breast cancer and hard-to-treat HER2+ refractory or drug resistant cancers. Both express highly elevated levels of HER3 receptor. Extensive scientific data is available validating the advantages and utility of Eos-001 in cancer cell lines, (breast, ovarian, prostate and glioblastoma) and xenograft mouse models for human cancer
- Observations
- Lower dose of targeted doxorubicin required
- Improved safety profile for targeted doxorubicin (e.g. no damage to heart tissue)
- Eos-001 is highly effective against first-line drug-resistant breast cancer cells and tumors
- Three (3) issued patents and a number of patent applications
Eos-001 Competition: Other Doxorubicin Products
Currently, doxorubicin is marketed either in native form (generic product), as liposomal formulation (branded product), or conjugated to albumin. In addition, other forms of nanoparticle-based doxorubicin approaches are being investigated. In addition to the unique structural properties of our Eosomes technology, Eos-001 differentiates from other marketed products in very impactful ways:
- Eos-001 is a specifically targeted product that delivers doxorubicin to the interior of the target cell limiting systemic exposure and resulting in higher efficacy at a lower dose and improved safety profile
- Eos-001 is uniquely highly active against HER2+ cells and tumors resistant to first-line therapies, and triple-negative breast cancer tumors
Eos-002: HER3-targeted Theranostic
- HER3-targeted Eosomes with manganese corrole payload (a new chemical entry)
- Manganese corrole is a porphyrin-like macrocyclic molecule with a manganese ion
- A theranostic product with therapeutic – cancer cell killing, and diagnostic – contrast properties which allows MRI imaging
- Can be applied to a variety of solid tumors, including Triple Negative Breast Cancer (TNBC) and hard-to-treat HER2+ drug resistant cancer cells
- Validated in cancer cell lines and xenograft mouse models for human cancer
- Issued U.S. and International patents and a number of patent applications
Eos-003
- C-Met targeted Eosomes with doxorubicin payload
- Applications: Drug-resistant and metastatic solid tumors that express elevated levels of c-Met
- US and International Patent applications
Eos-004: c-MET-targeted Theranostic
- C-MET-targeted Eosomes with manganese corrole payload
- Manganese corrole is a porphyrin-like macrocyclic molecule with a manganese ion
- A theranostic product with therapeutic-cancer cell killing, and diagnostic-contrast properties which allows MRI imaging
- Can be applied to a variety of solid tumors, including TNBC and hard-to-treat HER2+ drug resistant cancer cells
- Validated in cancer cell lines and xenograft mouse models for human cancer
- Multiple U.S. and International patent applications